VEGFA and skin basal cell carcinoma: Findings also suggest that this STR somatic mutation status might potentially be used to select BCC patients who could benefit from certain precision therapy, including hedgehog inhibitors, GSIs, anti-VEGF, proteasome inhibitors, and ICIs.